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Defective mitochondrial DNA homeostasis
in the substantia nigra in Parkinson disease
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Increased somatic mitochondrial DNA (mtDNA) mutagenesis causes premature aging in
mice, and mtDNA damage accumulates in the human brain with aging and neurodegenerative
disorders such as Parkinson disease (PD). Here, we study the complete spectrum of mtDNA
changes, including deletions, copy-number variation and point mutations, in single neurons
from the dopaminergic substantia nigra and other brain areas of individuals with Parkinson
disease and neurologically healthy controls. We show that in dopaminergic substantia nigra
neurons of healthy individuals, mtDNA copy number increases with age, maintaining the pool
of wild-type mtDNA population in spite of accumulating deletions. This upregulation fails to
occur in individuals with Parkinson disease, however, resulting in depletion of the wild-type
mtDNA population. By contrast, neuronal mtDNA point mutational load is not increased in
Parkinson disease. Our findings suggest that dysregulation of mtDNA homeostasis is a key
process in the pathogenesis of neuronal loss in Parkinson disease.
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S
omatic mitochondrial DNA (mtDNA) damage has been
associated with both normal aging and neurodegeneration1.
Accelerated mtDNA mutagenesis causes a premature aging
phenotype in mice2 and somatic mtDNA deletions have been
shown to accumulate with advancing age in post-mitotic tissues
including the brain, heart and skeletal muscle3. In the brain,
the dopaminergic substantia nigra is particularly susceptible
to somatic mtDNA deletions, which accumulate there at
substantially higher levels compared with other brainstem
nuclei, deep grey structures, or the cerebral and cerebellar
cortex. This predilection has led to the hypothesis that mtDNA
damage plays a role in the pathogenesis of Parkinson disease
(PD)4,5, where neurodegeneration of the substantia nigra is the
main pathological hallmark and widely accepted as the cause of
the cardinal clinical features6. mtDNA deletions were shown to
accumulate at similar levels in both individuals with PD and
healthy controls however4, and therefore do not provide a
sufficient explanation for the specific vulnerability of the
substantia nigra in PD. Mice accumulating high levels of
mtDNA deletion due to an error-prone mtDNA-polymerase
(POLG) show a concomitant increase in mtDNA copy number
which is associated with nigrostriatal survival and even resistance
to mitochondrial respiratory chain complex-I inhibition7.
Although a similar protective mechanism has not yet been
identified in humans, the importance of mtDNA copy-number
regulation is highlighted by the vulnerability of the substantia
nigra in inherited mtDNA-depletion disorders8,9 and the
increased risk of PD associated with genetic variation in genes
encoding key factors of mtDNA maintenance, such as the
mtDNA polymerase g (POLG) and mitochondrial transcription
factor A (TFAM)10,11. Nevertheless, the precise mechanism by
which mtDNA copy-number loss contributes to brain aging and
neurodegeneration remains unclear.
We hypothesized that dopaminergic substantia nigra neurons
in PD are rendered vulnerable to the effects of age-dependent
mitochondrial mutagenesis due to an underlying dysregulation of
mtDNA homeostasis. To test our hypothesis, we employed an
integrative approach to study the complete spectrum of mtDNA
changes in individual neurons from individuals with PD and
controls.
Our sample was derived from a population-based,
prospectively collected and extensively characterized cohort12.
To ensure our sample was homogenous and representative for
sporadic PD, we excluded known monogenic causes of PD
by whole-exome sequencing. Neuropathological examination
confirmed Lewy-body disease in all PD samples, whereas
control samples were negative for neurodegenerative markers
(Supplementary Table 1).
Our results show that dopaminergic substantia nigra neurons
of individuals with PD accumulate higher levels of somatic
mtDNA deletions, but not point mutations, compared with
age-matched controls. Moreover, in healthy individuals, mtDNA
copy number increases with age, thus maintaining the pool of
wild-type mtDNA population in spite of accumulating deletions.
Conversely, mtDNA copy number does not increase in
individuals with PD, resulting in depletion of the wild-type
mtDNA population. Our findings suggest that mtDNA home-
ostasis is impaired in the substantia nigra of individuals with PD.
Results
mtDNA copy number upregulation in aging substantia nigra.
First we characterized age-dependent mtDNA changes in
different neuronal populations from 21 controls aged 11–87 years
(Supplementary Table 1). We studied single dopaminergic
neurons from the ventrolateral tier (area A9) of the substantia
nigra pars compacta, pyramidal neurons from the frontal cortex
and Purkinje cells of the cerebellar cortex (Fig. 1). The proportion
of mtDNA molecules harbouring major arc deletions showed a
significant positive correlation with age in nigral neurons
(r¼ 0.39, P¼ 1 10 6; Fig. 2a), which is in line with previous
reports4,5. Total mtDNA copy number also increased with age
(r¼ 0.29, P¼ 4 10 4; Fig. 2b) and, strikingly, showed a
significant positive correlation with the level of deletion in each
neuron (r¼ 0.40, P¼ 2 10 6; Fig. 2c). Due to this concomitant
copy number increase, absolute levels of wild-type (non-deleted)
mtDNA did not decrease over time (r¼ 0.03, P¼ 0.3) in spite of
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Figure 1 | Laser microdissection (LMD) and workflow of mtDNA analyses in single neurons. (a–c) Representative examples of thick (20mm) sections of
fresh-frozen brain tissue stained with cresyl violet and used for LMD. (a) Pigmented, dopaminergic neurons were picked from the substantia nigra
pars compacta ( 100). (b) Pyramidal neurons were collected from the prefrontal cortex ( 200). (c) Purkinje cells where picked from the cerebellar
cortex ( 200). Oval holes in the tissue show where neurons have been microdissected and collected for analysis. (d,e) Microphotographs showing a
dopaminergic neuron of the substantia nigra before (d) and after (e) microdissection (400). Each neuron was collected individually in a 0.5 ml reaction
tube containing 15ml lysis buffer, lysed overnight and subjected to PCR analysis. Scale bars, 100mm (a–c) and 20mm (d,e).
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progressively increasing proportion of deletion. Whereas both
deletion and age appeared to correlate with mtDNA copy
number, using a multiple linear regression model, we found
that only deletion was a statistically significant predictor of copy
number (model: r¼ 0.40, R2¼ 0.18, P¼ 6.3 10 7; deletion:
b¼ 0.34, P¼ 6 10 5; age: b¼ 0.16, P¼ 0.06).
In frontal neurons and Purkinje cells, the level of mtDNA
deletion was generally low and did not increase with age
(Fig. 2d,g). Similarly, total mtDNA copy number showed no
significant change with age (Fig. 2e,h) or correlation with the
levels of deletion in these cells (Fig. 2f,i). Thus, our findings
demonstrate that aging substantia nigra neurons can robustly
upregulate mtDNA copy number and this correlates with the
levels of somatic mtDNA deletion in each cell. We suggest that
this reflects an intrinsic neuroprotective mechanism allowing
neurons to maintain an adequate pool of wild-type (non-deleted)
mtDNA molecules despite the age-dependent accumulation of
somatic deletion.
Evidence of impaired mtDNA copy-number regulation in PD.
We next investigated the integrity of neuronal mtDNA home-
ostasis in single neurons from individuals with validated sporadic
S. nigraa
P = 1× 10–6
r = 0.39
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Figure 2 | Age-dependent mtDNA changes in three neuronal populations from neurologically healthy controls. Single neurons from three brain areas of
neurologically healthy controls (n¼ 21) were analysed for mtDNA copy number and deletion level.(a–c) Single dopaminergic neurons of the pars compacta
of the substantia nigra (n¼ 147). (d–f) Pyramidal neurons of the frontal cortex (n¼ 193). (g–i) Purkinje cells of the cerebellum (n¼ 148). All three areas
were analysed from all subjects (n¼ 21). (a) In the substantia nigra, the fraction (%) of mtDNA harbouring major arc deletions increases significantly with
age (n¼ 147, P¼ 1 106; Pearson correlation). This is accompanied by a concomitant increase of mtDNA copy number (b), which correlates strongly
with the levels of mtDNA deletion in each neuron (n¼ 147, P¼ 2 10 6; Pearson correlation) (c). Frontal neurons show no increase in mtDNA deletion
levels (n¼ 193, r¼ 0.20, P¼0.06; Pearson correlation) (d) or copy number (n¼ 193, r¼0.11, P¼0.14; Pearson correlation) (e) with age and no
correlation between mtDNA copy number and levels of mtDNA deletion (n¼ 193, r¼ 0.12, P¼0.09; Pearson correlation) (f). Similarly, Purkinje cells of
the cerebellum show no increase in mtDNA deletion levels (n¼ 148, r¼ 0.10, P¼0.21; Pearson correlation) (g) or copy number (n¼ 148, r¼0.12,
P¼0.16; Pearson correlation) (h) with age and mtDNA copy number does not correlate with the levels of mtDNA deletion (n¼ 148, r¼ 0.09, P¼0.28;
Pearson correlation) (i). Each dot represents data from a single neuron. Statistics are derived from Pearson correlation and linear regression analyses.
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PD (n¼ 10) compared with neurologically healthy age- and
sex-matched controls (n¼ 10; Supplementary Table 1).
Dopaminergic nigral neurons from individuals with PD
contained significantly higher levels of mtDNA deletions than
nigral neurons from healthy controls (PD mean 40.2±20.0%,
controls mean 31.5±19.5%, P¼ 0.004; Fig. 3a). Notably, the
proportion of neurons with deletion levels exceeding 60%, which
has been postulated as a threshold for respiratory dysfunction in
cells13, was twice as high in the PD group (21.4%, n¼ 84)
compared with controls (10.8%, n¼ 74).
In spite of higher levels of deletion, mean total neuronal
mtDNA content was similar in the two groups (PD mean
31,271±13,217, controls mean 32,148±11,970 copies/neuron,
P¼ 0.57; Fig. 3b, total). Correlation of mtDNA copy number with
the age of the individual or mtDNA deletion levels in each neuron
revealed, however, striking differences between PD and controls.
In line with our initial findings, mtDNA copy number increased
significantly with age in the group of age-matched controls and
correlated with the level of deletion (r¼ 0.50, P¼ 5 10 5;
Fig. 3c), whereas in the PD group, the rate of copy number
P = 0.04
r = 0.22











































































































Figure 3 | Impaired mtDNA maintenance in the dopaminergic substantia nigra of patients with PD. Data show analyses in single dopaminergic
substantia nigra neurons from individuals with PD (n¼84 neurons from 10 individuals) and age-matched controls (n¼ 74 neurons from 10 individuals).
(a) Deletion levels are significantly higher in PD compared with controls (P¼0.004; Mann–Whitney U test). Error bars show s.d. (b) Scatter plot of total
and wild-type (non-deleted) mtDNA. Total mtDNA copy number is similar in PD and controls, but the levels of wild-type mtDNA are significantly
decreased in PD (P¼0.006; Mann–Whitney U test). Bars show mean. (c,d) Linear regression of neuronal mtDNA copy number plotted against deletion
levels; each point shows data from a single neuron. The correlation between mtDNA copy number and deletion is poor in PD (P¼0.04, r¼0.22) compared
with controls (P¼ 5 10 5, r¼0.50; Pearson correlation). (e) Fraction of total dopaminergic substantia nigra neurons of individuals with PD and controls
distributed according to wild-type (non-deleted) mtDNA content. The fraction of neurons with very low (o10,000) wild-type mtDNA copy number is
significantly enriched in PD (Ctrl 2.7% versus PD 14.3%, P¼0.01; Fisher’s exact test), whereas in controls, the majority of neurons contain at least 15,000
copies of non-deleted mtDNA. Ctrl: controls. *Po0.05, **Po0.01.
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increase was substantially less pronounced (r¼ 0.22, P¼ 0.04;
Fig. 3d) and, in the presence of higher levels of deletion,
resulted in quantitative loss of wild-type mtDNA (PD mean
18,109±9,421, controls mean 20,876±7,839 copies/neuron,
P¼ 0.0056; Fig. 3b, wild type). Although the degree of wild-type
mtDNA loss appeared mild at the group level, substantial
variation was seen between individual cells. Notably, the subset
of neurons with severe wild-type depletion, defined as o10,000
copies per neuron, was significantly higher in the PD group
(PD 14.3%, controls 2.7%, P¼ 0.01; Fig. 3e). This corresponds to
a loss of B70% of the mean wild-type mtDNA population in
these neurons, which is higher than the estimated threshold for
respiratory dysfunction13.
mtDNA deletion levels were generally low in frontal
neurons (PD mean 15.50±3.75%, controls mean 15.57±3.90%,
P¼ 0.1) and Purkinje cells (PD mean 13.07±3.90%,
controls mean 13.04±3.70%, P¼ 0.8) of both individuals
with PD and controls (Fig. 4a,b). mtDNA copy number in
these cells showed subtle differences between the groups
(Fig. 4c,d), but there was no correlation with the levels of
deletion (Fig. 4e–h).
No evidence of impaired mitochondrial biogenesis in PD. To
investigate whether the loss of wild-type mtDNA in the PD group
reflects a defect of mtDNA maintenance specifically, or an overall
defect in mitochondrial biogenesis, we investigated markers of
mitochondrial mass and biogenesis in the substantia nigra by
immunohistochemistry in situ, in brain sections from individuals
with PD and healthy controls. Total mitochondrial mass was
assessed using the mitochondrial membrane marker porin,
and mitochondrial biogenesis signalling was assessed via the
peroxisome proliferator-activated receptor gamma co-activator
1-alpha (PGC-1a), a transcription co-activator that regulates
mitochondrial biogenesis. Morphometric analyses of the sections
revealed no detectable difference in either intensity or cellular
distribution of the porin or PGC-1a staining between individuals
with PD and controls, suggesting no overt change in mitochon-
drial biogenesis signalling or total mass in dopaminergic neurons
(Figs 5 and 6).
mtDNA somatic point mutations are not elevated in PD. To
assess whether point mutations also contribute to neuronal
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Figure 4 | mtDNA analyses in frontal and cerebellar neurons. mtDNA analyses in single pyramidal neurons from frontal cortex and Purkinje cells of the
cerebellum of individuals with PD (n¼ 73 frontal neurons and 76 Purkinje cells from 10 individuals) and healthy controls (n¼ 78 frontal neurons and 71
Purkinje cells from 10 individuals). (a,b) mtDNA deletion levels. (c,d) mtDNA copy number. Error bars show s.d. Comparison by Mann–Whitney U test.
*P¼0.04, **P¼0.005. (e–h) Correlation between mtDNA copy number and deletion levels in frontal cortex (Ctrl: r¼0.04, P¼0.73; PD: r¼ 0.09,
P¼0.4; Pearson correlation) (e,f) and cerebellum (Ctrl: r¼ 0.01, P¼0.90; PD: r¼ 0.02, P¼0.87; Pearson correlation) (g,h) from individuals with PD
(f,h) and controls (e,g). Ctrl: controls.
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a B5 kb fragment of mtDNA (rCRS 1157–5924) in a total of
184 single dopaminergic substantia nigra neurons from the 10
individuals with PD and 10 matched controls. The sequenced
fragment was localized away from the deletion region to ensure
it represented the total mtDNA population of each neuron
(for details see the ‘Methods’ section and Fig. 7a,b). Sequence data
from 144 neurons successfully passed quality control and were
used in the analyses. High-sequence coverage (Fig. 7c) allowed for
detection of single-nucleotide variants (SNVs) as low as at a
heteroplasmic frequency (HF) of 0.1% (Fig. 7d). The point
mutation frequency was estimated as number of SNVs per
1,000 bp mtDNA.
Homoplasmic (that is, affecting all mtDNA molecules) SNVs
(HF498%) had a mean frequency of 0.95±0.47/1,000 bp per
neuron and were shared by all neurons of an individual,
consistent with being inherited. The number of transitions
PD Ctrl PD Ctrl
PCG1-α Porin
Figure 5 | Immunohistochemistry for porin and PGC-1a in dopaminergic substantia nigra neurons of individuals with PD and controls.
Representative sections are shown from three individuals with PD and three controls (Ctrl). There is no detectable difference in staining intensity or







Figure 6 | Single-cell montage of porin and PCG-1a-stained dopaminergic substantia nigra neurons of individuals with PD and controls. The
photomontages show representative examples of individual dopaminergic neurons from the ventrolateral tier of the substantia nigra pars compacta,
stained with antibodies against porin (a) and PGC-1a (b). Each row shows neurons from the same individual. In both panels, the top five rows are controls
and bottom six rows individuals with PD. Magnification: 400.
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(exchange between two purine or pyrimidine bases;
0.92±0.46/1,000 bp) greatly outnumbered that of transversions
(exchange between a purine and a pyrimidine base;
0.03±0.07/1,000 bp), in line with the high transition bias of
mammalian mtDNA14. The mean load of heteroplasmic (that is,
affecting a fraction of mtDNA molecules) SNVs (HF: 0.1–98%)
was 33.14±10.03/1,000 bp per neuron and most of these
(31.68±10.96) clustered at the low-frequency spectrum
(HF 0.1–1%) in both PD and control groups (Fig. 7d). The vast
majority (98.8%) of the heteroplasmic changes were not shared
across the neurons of an individual, suggesting that these were
indeed true somatic changes. Heteroplasmic changes occurred in
all sequenced mtDNA genes, with small inter-genic differences
(Supplementary Table 3).
The overall burden of heteroplasmic SNVs was similar in
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Figure 7 | Amplification and deep-sequencing of mtDNA from single dopaminergic substantia nigra neurons of individuals with PD and controls.
(a) Schematic representation of human mtDNA, indicating the major arc (grey arc), where the vast majority of mtDNA deletions occur, and the position of
the 4,767 bp fragment used for ultra-deep sequencing (magenta arc). mtDNA genes are coloured by type of transcript and designated by standard
nomenclature. Genes encoding tRNAs are coloured green and designated by the one-letter code of their corresponding amino acid. (b) PCR products were
amplified from single-cell lysates and analysed by agarose gel electrophoresis before sequencing. Samples with low (*) or no (#) amplification were
omitted. (c) Mean sequencing depth and coverage of the mtDNA fragment after completed quality control. The solid black line shows the mean depth for
all samples per mtDNA position and the shaded grey line corresponds to the 95% confidence interval (CI). Indicatively, 95% of the sequence was covered
at 412,000 depth and 80% at 450,000 depth. (d) Total burden of mtDNA SNVs in single dopaminergic neurons of the substantia nigra plotted
against the base 10 logarithm of heteroplasmy frequency (HF). Bars show 95% CIs. Point mtDNA variation is found at generally low levels in nigral neurons
and the majority of variants cluster at heteroplasmic frequencies below 1%. There is no difference in point mutational burden between individuals with PD
(blue) and controls (red).
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34.82±9.55 variants per neuron, P¼ 0.8) across the range of HF
(Fig. 8a,b). The physical distribution of variation showed no
significant gene-specific, or other regional difference between PD
and controls (Fig. 8c and Supplementary Table 3). The transition
to transversion ratio (Ti/Tv) of heteroplasmic SNVs was similarly
low in both groups (PD 2.27±1.63, controls 2.03±1.48, P¼ 1)
implying a high fraction of random mutation which resonated
with the high proportion of somatic mutation among the
heteroplasmic changes (Fig. 8d). The proportion of G:C to
T:A transversions which are commonly associated with
oxidative DNA damage15 was also similar in the two groups
(PD 0.28±0.08, controls 0.32±0.09, P¼ 0.6), implying that
oxidative stress is not a major factor in somatic mtDNA
mutagenesis in PD (Fig. 8e).
Discussion
In this work, we characterize the complete spectrum of neuronal
mtDNA changes in aging and PD, and measure the range of
mtDNA damage in the same neuron. We show that deletions and
copy-number regulation, but not point mutations, are the main
determinants of somatic, neuronal mtDNA damage in humans.
Moreover, we show that dynamic regulation of mtDNA copy
number occurs in aging substantia nigra neurons allowing them
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Figure 8 | Ultra-deep mtDNA sequencing in single dopaminergic neurons of the substantia nigra. (a,b) Burden of mtDNA SNVs per neuron plotted
against heteroplasmy frequency (HF). mtDNA point mutational burden is similar in individuals with PD and controls across the range of HF. Error bars show
95% confidence intervals (CIs). (c–e) Distribution and type of mtDNA SNVs in neurons of individuals with PD and controls. (c) Physical distribution of low-
frequency SNVs (0.1–1%) on the sequenced mtDNA fragment in individuals with PD and controls. Each variant is represented by a vertical black streak to
allow differentiation between areas with low mutation frequencies (lighter shade) to high-mutation frequencies (darker shade). mtDNA positions and
physical gene location are shown in scale on the x axis. There is no significant difference in regional SNVs distribution between regions/genes or between
individuals with PD and controls. (d) Ratio of mtDNA transitions to transversions (Ti/Tv) at low (0.001–0.01) and high (0.01–0.98) heteroplasmic
frequencies. PD and controls show no difference in transition/transversion composition across heteroplasmic frequencies (w2). (e) The proportion of
G:C4T:A tranversions is similar in individuals with PD and controls. Error bars show 95% CIs.
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accumulating somatic deletions, similar to what was shown in the
POLG mutator mouse7. Strikingly, this compensation appears
to be blunted in the context of PD resulting in depletion of the
wild-type mtDNA pool. We believe this may contribute to the
respiratory deficiency observed in these neurons16, thus playing
an important role in the cascade of neurodegeneration.
The mechanism underlying the apparent impairment of
mtDNA upregulation in PD could reflect a defect of overall
mitochondrial biogenesis or mtDNA homeostasis specifically.
Our immunohistochemistry experiments in the substantia
nigra detected no measurable difference in the neuronal protein
levels of mitochondrial marker porin, or master activator of
mitochondrial biogenesis PGC-1a. One limitation of these
experiments is that immunohistochemistry has limited sensitivity
and would not detect subtle changes of expression. Nevertheless,
these results suggest that there is no major impairment in overall
mitochondrial biogenesis in PD. It is therefore more likely that
the observed lack of mtDNA increase we found in PD reflects a
defect in mtDNA homeostasis. This is in line with inherited
disorders of mtDNA maintenance due to POLG or helicase
Twinkle mutations, where the combination of mtDNA depletion
and deletion without an overall change in mitochondrial mass
leads to respiratory failure and severe substantia nigra degenera-
tion8,9. Impaired mtDNA maintenance has indeed been shown to
be particularly deleterious for the substantia nigra and more likely
to cause nigrostriatal degeneration compared with other
mitochondrial defects17.
mtDNA maintenance is mediated via a complex interaction
of several molecular processes including mtDNA replication
and repair, mitochondrial nucleotide pool maintenance,
mitochondrial dynamics and quality control18,19. It is possible
that impairment of one or more of these processes occurs in PD
due to genetic variation and/or epigenetically mediated altered
transcriptional regulation of the factors involved. Further
research is warranted to uncover the mechanisms underlying
abnormal mtDNA maintenance in the substantia nigra of
individuals with PD.
Our findings appear to contradict recent reports of total mtDNA
depletion20 and higher point mutational load21 in the brain of
individuals with PD. Since those studies were performed in tissue
homogenate and not individual neurons, however, they are likely
to be confounded by the substantial neuronal loss and gliosis in
the PD samples, rather than reflect true changes in dopaminergic
neurons. It has been shown that accurate determination of
mtDNA quantity in neurodegeneration requires experiments in
isolated neurons, and that measurements in homogenate can lead
to substantially over- or underestimation of mtDNA quantity
depending on underlying tissue pathology22.
Another important advantage of our study over previous
experiments is the ultra-deep coverage of our sequencing
experiments. Our high sequencing depth allowed the detection
of variants down to a frequency of 0.1%, which, with an average
of B30,000 mtDNA molecules per neuron, corresponds to as few
as 30 mtDNA molecules. Thus we were able to confidently assess
point mutations at heteroplasmic frequencies below 1%, where we
show that the vast majority (96%) of somatic mtDNA point
mutations occurs in neurons. This spectrum of mtDNA variation
had been unexplored by previous studies due to insufficient
sequencing depth limiting their lower detection threshold to 1%
heteroplasmy. Furthermore, by selecting our amplification and
sequencing target outside of the commonly deleted mtDNA
region, our sequence data reflects the entire mtDNA population
of each neuron, comprising both structurally intact and deleted
molecules.
In conclusion, our findings have important implications
for therapy-oriented research. Pharmacological upregulation of
mtDNA levels may rescue neuronal respiration and exert a
neuroprotective effect in PD. Administration of agents promoting
mitochondrial biogenesis via the peroxisome proliferator-
activated receptor gamma pathway have indeed been associated
with a significantly lower risk for PD (ref. 23). We believe that
this effect may be at least partly due to compensation for somatic
mtDNA damage. While further studies are needed to elucidate
the molecular mechanisms underlying mtDNA copy-number
regulation in aging and neurodegeneration, we believe that these
may be exploited to design novel neuroprotective therapies.
Methods
Subject cohort. Tissue was obtained from the Park-West study, a prospective
population-based cohort which has been longitudinally followed-up for 9 years
and has been described in detail12. All included subjects in the PD group
(n¼ 10) fulfilled the National Institute of Neurological Disorders and Stroke24 and
the U.K. PD Society Brain Bank25 diagnostic criteria for PD at their final visit.
Whole-exome sequencing was performed on all individuals with PD using
Roche-NimbleGen Sequence Capture EZ Exome v3 kit and paired-end 100nt
sequencing on the Illumina HiSeq platform (unpublished material). To exclude
monogenic effects which could confound our study, genes associated with familial
parkinsonism (SNCA, LRRK2, VPS35, EIF4G1, DCTN1, CHCHD2, PARK2, PINK1,
PARK7, ATP13A2, PLA2G6, FBXO7, COQ2 and SLC6A3) were extracted and
screened with no evidence of known pathogenic mutations (data available on
request). In addition, coverage analysis of the SNCA exons showed no evidence of
copy-number variation. Controls had no known neurological disease and were
matched for age (t test; P¼ 0.16) and gender (Supplementary Table 1). Individuals
with PD and controls had no history of mitochondrial disorder or use of
antiretroviral medication which may affect mtDNA homeostasis. A complete list of
the medication used by the individuals with PD during at least the last 12 months
before death is shown in Supplementary Table 2.
Neuropathological examination. Brain tissue from individuals with PD and
controls was collected at autopsy. The brain was split sagittally along the corpus
callosum. One hemisphere was fixed whole in formaldehyde and the other
coronally sectioned in 1 cm slices which were individually snap-frozen in liquid
nitrogen. There was no significant difference in post-mortem or fixation time
between individuals with PD and controls. Neuropathological examination was
performed on the following brain areas from all samples of individuals with PD
and controls who were above the age of 40 years: frontal cortex, hippocampus,
striatum (nucleus lentiformis) cerebellum and mesencephalon (containing the
substantia nigra) at the level of the third cranial nerve and pons at the level of
the locus coeruleus. Serial sections (3mm) of formalin-fixed, paraffin embedded
tissue were stained with haematoxylin and eosin using a standard protocol
and immunohistochemistry with antibodies against alpha-synuclein (Leica,
NCL-L-ASYN, dilution 1:20), tau (DAKO, A0024, dilution 1:1,000), b-amyloid
(DAKO, M0872, dilution 1:50), PGC-1a (Abcam, ab54481, dilution 1:100) and the
mitochondrial membrane marker porin (Abcam, ab14734, dilution 1:10,000).
Staining was performed in an automated stainer (Ventana Benchmark Ultra
Stainer) and visualization using Ventana 760-500 Ultra View Universal DAB
detection kit. Antibodies were diluted in Ventana Antibody Diluent (Ventana
251-018). Porin and PGC-1a staining were performed manually with the antibody
diluted in TBS containing 0.1% Tween-20. MACH4 Universal HRP-polymer
(Biocare M4U534) and DAB chromogen kit (Biocare DB801) were used for
visualization.
Tissue morphology and staining of neurodegenerative markers were assessed by
an experienced neuropathologist. Staining and assessment of porin and PGC-1a
were blinded for disease status. These were initially assessed visually in situ by
two researchers who were highly experienced in mitochondrial staining and
histopathology (C.T. and I.F.). Subsequently, we performed a more standardized
assessment independent of surrounding tissue morphology, which may affect
contrast perception and suggest disease status. High-resolution microphotographs
were taken at  400 magnification using a light microscope (Leica) equipped with
a Zeiss AxioCam MRc5 camera and Zen 2011 software (Carl Zeiss MicroImaging
GmbH, Jena, Germany) under standardized conditions. Randomly picked
dopaminergic single neurons of the substantia nigra pars compacta were cut from
each photograph and stacked on a uniform black background using Fiji v2.0.0
(ref. 26). Due to the presence of neuromelanin, interfering with automated
measurement procedures, the photomontages were evaluated visually by the same
researchers (Fig. 6). Pathology findings are summarized in Supplementary Table 1.
Single-neuron laser microdissection (LMD) and lysis. For the LMD,
20 mm-thick sections were cut from frozen ( 80 C) blocks of substantia nigra,
frontal cortex and cerebellum using a cryostat (Leica CM 1950) and mounted on
membrane slides 1.0 PEN (Zeiss). Tissue sections were air-dried for 1 h, stained
with cresyl violet (0.25% in ddH2O) for 10 min and dehydrated in graded ethanol
series (75, 90 and 100%). LMD was performed on a PALM Laser microdissection
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microscope (Zeiss). In the substantia nigra, the pars compacta was identified based
on localization, morphology and neuromelanin pigmentation. Neuromelanin
positive (dopaminergic) neurons were collected from the ventrolateral tier
(A9 area), which is consistently and severely affected by neurodegeneration in PD.
Pyramidal neurons and Purkinje cells were collected from the frontal cortex and
cerebellar cortex, respectively. Following positive identification, neurons were
measured for surface area and collected individually, one cell per tube.
A total of 871 single neurons were collected from the three brain areas of 10
individuals with PD and 21 controls. Of these, 786 samples successfully passed
quality control and were used in the analyses. Analysis of neuronal surface area
showed no significant difference between PD and control groups for each type of
neuron. Collected cells were individually lysed in 15 ml lysis buffer (50 mM Tris
pH 7.4, 0.5% Tween-20, 200mg ml 1 proteinase K) overnight at 56 C, centrifuged
(5 min, 10,000 r.p.m., 4 C), incubated for 10 min at 95 C to inactivate proteinase
K, and centrifuged again. Each cell lysate was subsequently divided and used in
downstream mtDNA analyses comprising determination of total copy-number,
fraction of molecules harbouring deletions and ultra-deep sequencing for assessing
the load of point mutations. In this way, all three types of mtDNA changes were
determined in the same single neurons.
mtDNA copy number and deletion analysis. Total mtDNA copy number and the
fraction of major arc deletion were determined in 8–10 single neurons per brain
region from each of 10 individuals with PD and 21 controls: substantia nigra pars
compacta (PD, n¼ 74; control: n¼ 147), frontal cortex (PD, n¼ 73; control,
n¼ 188) and cerebellar Purkinje cells (PD, n¼ 76; control, n¼ 150). Our assay
detected specifically deletions of the mtDNA major arc, that is, the region between
the origins of replication for the light and heavy strand (Fig. 6a), where the vast
majority of single and nearly all multiple deletions are known to occur27. Copy
number and deletion analysis were performed simultaneously in the same neuron,
using a duplex real-time PCR assay to detect a commonly deleted (MTND4) and
rarely deleted (MTND1) targets on the mitochondrial genome27,28. The following
primers, probes and conditions were used. MTND1: forward primer: 50-CCCTAAA
ACCCGCCACATCT-30, reverse primer: 50- GAGCGATGGTGAGAGCTAA
GGT-30 , TaqMan MGB probe: 50-FAM-CCATCACCCTCTACATCACCGCCC-30 .
MTND4: forward primer: 50-CCATTCTCCTCCTATCCCTCAAC-30 , reverse
primer: 50-CACAATCTGATGTTTTGGTTAAACTATATTT-30 , TaqMan MGB
probe: 50-VIC-CCGACATCATTACCGGGTTTTCCTCTTG-30 . Cell lysate (2 ml)
were used per quantitative PCR (qPCR) reaction and all samples were run in
triplicate. Amplification was performed on a 7500 fast sequence detection system
(Life Sciences) using TaqMan Fast Advanced Master Mix (Thermofisher). Thermal
cycling consisted of one cycle at 95 C for 20 s and 40 cycles at 95 C for 3 s and
60 C for 30 s.
For absolute quantification, target amplification was compared with a standard
curve made from a serial dilution containing equal amounts of PCR-generated and
purified full-length MTND1 and MTND4 template (102–106 copies per ml).
MTND1 is rarely deleted and reflects total mtDNA copy number whereas MTND4
only amplifies molecules not harbouring major arc deletions. The percentage of
deletion was calculated from the difference of the two as previously described27.
Genomic blood-DNA from two healthy individuals was used as an internal control
in each experiment.
Single-neuron ultra-deep mtDNA sequencing. To assess mtDNA SNVs down to
very-low heteroplasmy levels, we performed PCR amplification and ultra-deep
sequencing of a 4,767 bp mtDNA fragment (rCRS 1157-5924) spanning two rRNA
(MT-RNR1, MT-RNR2), 10 tRNA (MT-TV, L1, I, Q, M, W, A, N, C, Y) and two
peptide (MT-ND1, MT-ND2) genes (Figs 7a,c and 8c). mtDNA sequencing was
performed in 184 individual dopaminergic substantia nigra neurons, comprising
8–10 neurons from each of the individuals with PD (n¼ 10) and age-matched
controls (n¼ 10). The presence of high levels of mtDNA deletions could introduce
substantial selection bias in the amplification process towards specific mtDNA
populations. mtDNA molecules harbouring deletions between the primer binding
sites would be selectively overamplified due to their small size and therefore
overrepresented in the sequencing results. Conversely, deletions spanning at least
one primer binding site would prevent amplification of these molecules skewing
towards non-deleted populations. To avoid this potentially substantial selection
bias, we chose the size and location of the amplicon to be away from the major arc
region where the vast majority of large deletions occur. Thus our sequencing data
are representative for the entire mtDNA population in each neuron tested.
Amplification of each sample was performed in a 50 ml reaction using 5 ml of cell
lysate as template, forward primer 50-TTAAAACTCAAAGGACCTGGC-30 and
reverse primer 50-GACCTAGTCAACGGTCGGCGAAC-30 . To minimize PCR-
introduced sequence variation, we used Prime-STAR GXL DNA polymerase
(reported error rate¼ 1 10 5, Takara Bio). Thermal cycling comprised one cycle
at 92 C for 2 min and 35 cycles of 92 C for 10 s, 63 C for 30 s and 68 C for 8 min.
PCR products were quality controlled by agarose gel electrophoresis using 5 ml
sample and quantitated via picogreen fluorometric assay using 2 ml sample at 1:100
dilution. Samples showed concentrations in the range of 9.1–72.4 ng ml 1.
Subsequently, samples were normalized in 50 ml of nuclease-free water using
0.30–1.00 mg of stock DNA material and sonicated on a Covaris LE220 (Covaris) to
a target insert size of B400 bp. Libraries were prepared using the GSL standard
whole-genome library prep protocol with 1.8 clean-up to retain all fragments
r400 bp insert size and quality controlled by qPCR (KA PA SYBR FAST qPCR,
Kapa Biosystems). Products were sequenced using paired-end 125nt sequencing on
the Illumina HiSeq 2500, v4 chemistry and generating B1 Gb of data per sample.
Sequencing was performed at HudsonAlpha Institute for Biotechnology
(Huntsville, AL).
Sequence data analysis. Illumina paired-end reads in FASTQ format were
mapped to the rCRS reference sequence using BWA aligner v6.2 (ref. 29). From the
resulting alignments, only bases with a PHRED-score Z30 and a mapping quality
of Z30 were used for the subsequent analyses. SAMtools version 1.3-8 (ref. 30) was
used to sort and index the alignments and to remove duplicates. Pileup files
were generated for each of the samples using the mpileup utility of SAMtools.
Subsequently, pileup files were parsed to calculate the relative frequencies of each
nucleotide per mtDNA position. Variants were called requiring a minimum
coverage of 30 reads for the variant base and the lowest limit for heteroplasmic
detection was set to 0.1%. mtDNA haplotype were defined using the mt-classifier
script (v.0.2; ref. 31) and requiring HF Z80% for the variants defining the
haplotype in each neuron. Samples were quality controlled for haplotype
consistency across all neurons of an individual. Samples with inconsistent
haplotypes were discarded from the analyses as they were likely to be
contaminated. A total of 144 samples (144 neurons from 10 individuals with
PD and 10 controls) passed quality filters and were used for the analyses of
mutational burden. For the statistical analyses, variants were categorized in three
groups according to HF: low-frequency heteroplasmy (HF 0.1–1%), high-frequency
heteroplasmy (HF 1–98%) and homoplasmy (98–100%).
Statistical analyses. Statistical analyses were performed in SPSS (v.20.0.0.1),
Graph Pad Prism (v.6) and R (v.3.2.3). Group comparisons for mtDNA deletion
and copy number were done by Mann–Whitney U test. Comparison/correlation
between different types of mtDNA changes and/or age was done by linear
regression analysis. To assess whether age or level of mtDNA deletion
was a stronger determinant of mtDNA quantity in a neuron, we performed
two independent single linear regression analyses using age or copy number as
predictors. To quantify the net association of each of the predictors with the
outcome variable we performed a multiple linear regression model. Comparison of
point mutational load between groups was done by w2 test. Mutational burden
distribution between different mtDNA genes in individuals with PD and controls
was compared by ANOVA, followed by group comparisons by t tests and
Bonferroni correction for multiple testing. Investigators were blinded to the state of
samples (PD or control) for all mtDNA studies. Tissue sections from which the
neurons were microdissected were identified by unique numbers only.
Ethical considerations. These studies were approved by the Regional Committee
for Medical and Health Research Ethics, Western Norway (REK 131/04 and REK
2010/23). Informed consent was obtained from all subjects.
Data availability. The pipeline for mtDNA sequence analysis was implemented
using a script in Python 2.7 which is available on request. The data sets generated
and/or analysed during the current study are available from the corresponding
author on reasonable request.
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